Media Summary: At the EASD 2025 Annual Meeting in Vienna, the AHA 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Professor Stephen Nicholls (Monash ... Learn from Eli Lilly's Top Medical Director Nadia N Ahmad on

Frias Tirzepatide Overview Of Surpass - Detailed Analysis & Overview

At the EASD 2025 Annual Meeting in Vienna, the AHA 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Professor Stephen Nicholls (Monash ... Learn from Eli Lilly's Top Medical Director Nadia N Ahmad on In this short interview, Dr Ellen Apperloo (University Medical Center Groningen, Groningen, NL) discusses the key outcomes of ... Host Kate Glasenapp, DNP, APNP-BC, BC-ADM, CDCES, CBN, CSOWM Assistant Professor, Division of Endocrinology ... Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of

Photo Gallery

Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes
Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM | Med Journal Club
EASD 2025: SURPASS-CVOT - A Comparison of Tirzepatide and Dulaglutide
SURPASS CVOT: Dr. Deepak Bhatt Breaks Down Tirzepatide CV Data
Tirezpatide: rationale and MOA with Juan Frías, MD
AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide for Heart Failure in T2D
Tirzepatide: the SURMOUNT-1 trial by Nadia Ahmad
Tirzepatide: How Does It Work for Weight Loss? │ Pharmacology
Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis
Peters on Tirzepatide: 'Impressive, but We Need to Know More'
A Bite in Time | Tirzepatide: The Complete Story – Beyond GLP-1
Tirzepatide: A New Frontier for Diabetes Management
View Detailed Profile
Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes

Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes

So if we look at the

Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM | Med Journal Club

Tirzepatide vs Dulaglutide for Cardiovascular Outcomes (SURPASS-CVOT) | NEJM | Med Journal Club

In this journal club

EASD 2025: SURPASS-CVOT - A Comparison of Tirzepatide and Dulaglutide

EASD 2025: SURPASS-CVOT - A Comparison of Tirzepatide and Dulaglutide

At the EASD 2025 Annual Meeting in Vienna, the

SURPASS CVOT: Dr. Deepak Bhatt Breaks Down Tirzepatide CV Data

SURPASS CVOT: Dr. Deepak Bhatt Breaks Down Tirzepatide CV Data

In

Tirezpatide: rationale and MOA with Juan Frías, MD

Tirezpatide: rationale and MOA with Juan Frías, MD

Juan

AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide for Heart Failure in T2D

AHA 25: SURPASS-CVOT:Tirzepatide vs Dulaglutide for Heart Failure in T2D

AHA 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Professor Stephen Nicholls (Monash ...

Tirzepatide: the SURMOUNT-1 trial by Nadia Ahmad

Tirzepatide: the SURMOUNT-1 trial by Nadia Ahmad

Learn from Eli Lilly's Top Medical Director Nadia N Ahmad on

Tirzepatide: How Does It Work for Weight Loss? │ Pharmacology

Tirzepatide: How Does It Work for Weight Loss? │ Pharmacology

Learn about

Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis

Tirzepatide Shows Kidney Benefits in T2D: SURPASS Trials Analysis

In this short interview, Dr Ellen Apperloo (University Medical Center Groningen, Groningen, NL) discusses the key outcomes of ...

Peters on Tirzepatide: 'Impressive, but We Need to Know More'

Peters on Tirzepatide: 'Impressive, but We Need to Know More'

Dr Anne Peters discusses

A Bite in Time | Tirzepatide: The Complete Story – Beyond GLP-1

A Bite in Time | Tirzepatide: The Complete Story – Beyond GLP-1

Host Kate Glasenapp, DNP, APNP-BC, BC-ADM, CDCES, CBN, CSOWM Assistant Professor, Division of Endocrinology ...

Tirzepatide: A New Frontier for Diabetes Management

Tirzepatide: A New Frontier for Diabetes Management

On this episode, we

ACC 26: SURPASS-CVOT - Tirzepatide Versus Dulaglutide on Cardiorenal Outcomes in Type 2 Diabetes

ACC 26: SURPASS-CVOT - Tirzepatide Versus Dulaglutide on Cardiorenal Outcomes in Type 2 Diabetes

Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of